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Epstein–Barr virus (EBV) infects B cells, resulting in the outgrowth of immortalised lymphoblastoid cell lines (LCLs). Here,
we demonstrate through the use of intracellular staining that interleukin-1b (IL-1b) is expressed in LCLs and investigate the
influence of the individual latent proteins on the expression of IL-1b. Using RT-PCR, IL-1b was shown to be up-regulated in
EBV-transformed LCLs as well as in group III Burkitt’s lymphoma (BL) cell lines, compared with group I BL cell lines. The
up-regulation of IL-1b message could be mediated by the latent membrane protein-1, EBV nuclear proteins 2, 3, 4, and 6
genes. Electrophoretic mobility shift assays (EMSAs) demonstrated that the 2300 region of the IL-1b promoter, which
contains a nuclear factor-kB (NF-kB) binding site, contained a functional RBP binding site. Binding of RBP to this site could
be inhibited by addition of EBV nuclear proteins 3 and 6, suggesting that these proteins displace RBP from its recognition
sequence, removing transcriptional repression and allowing gene transcription to occur. In group I BL cells, containing low
levels of NF-kB, only RBP binding was observed in EMSAs, whereas NF-kB binding could be demonstrated in EBV-
transformed B cell lines containing high levels of activated NF-kB. In addition, the expression of latent membrane protein-1
led to activation of NF-kB that was capable of binding the IL-1b promoter. The study demonstrates that EBV can up-regulate
IL-1b expression, possibly by using RBP, NF-kB, or both. © 1998 Academic Press
INTRODUCTION
After Epstein–Barr virus (EBV) infection in vitro, B cells
express the full set of EBV latent antigens that act to
initiate and maintain B cell growth. Expression of these
latent proteins, which include EBV nuclear proteins
(EBNAs) 1–6 and the latent membrane proteins (LMP-1
and -2), results in the transformation of B cells and the
generation of lymphoblastoid cell lines (LCLs). EBNAs 3,
4, and 6 (also known as EBNAs 3a, 3b, and 3c) are a
family of related proteins that share structural homolo-
gies and have a similar genomic organisation (Le Roux
et al., 1994). Studies have shown that EBNAs 2, 3, and 6
and LMP-1 are essential for transformation (Tomkinson
and Kieff, 1992; Tomkinson et al., 1993).
EBV-positive cell lines derived from Burkitt’s lymphoma
(BL) can be classified according to their cell surface
phenotype (Rowe et al., 1986). During early passage in
vitro, EBV-positive BL cells (group 1) grow independently,
are sensitive to changes in growth conditions, and ex-
press the EBV latent protein EBNA 1 and the cell surface
markers BLA (CD77) and CD10. With continuous in vitro
culturing, some BL cells progress toward a group III
phenotype (a phenotype similar to that observed for
LCLs), growing in clumps and expressing adhesion mol-
ecules, additional B cell activation antigens on their
surface and the full set of EBV latent antigens. In EBV-
negative BLs, continuous in vitro culturing leads to a
similar transition where the cell phenotype changes from
a resting B cell to an activated B cell that also expresses
adhesion molecules and B cell activation markers
(Khanna et al., 1996).
The EBNA 2, 3, 4, and 6 gene products have been
shown by either immunoprecipitation, the yeast two-
hybrid system, or in vitro binding assays to interact with
the DNA-binding protein RBP-Jk or its isoform RBP-2N
(Hsieh and Hayward, 1995; Krauer et al., 1996; Marshall
and Sample, 1995; Robertson et al., 1995, 1996; Zhao et
al., 1996). RBP (also known as RBP-Jk/2N or CBF1) has
been identified as a transcriptional repressor in mam-
malian cells and functions by binding to DNA and inhib-
iting the transactivation of genes (Hsieh and Hayward,
1995). When associated with EBNA 2, RBP is still able to
bind DNA through interaction with its consensus DNA
binding site; however, the RBP repression domain is
masked (Robertson et al., 1995, 1996). After the formation
of the EBNA 2–RBP–DNA complex gene, transactivation
rather than repression occurs (Ling et al., 1994). In con-
trast, the interaction of RBP with the EBNA 3 family gene
products (EBNAs 3, 4, and 6) appears to prevent RBP
binding to DNA (Robertson et al., 1996), thereby prevent-
ing RBP-mediated repression. It is apparent that EBV
contains a number of proteins that are intricately in-
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volved in regulating or controlling gene expression via
interaction with RBP.
RBP has been identified as a DNA-binding protein that
binds to the DNA consensus sequence 5-GTGGGAAA
(Dou et al., 1994). Studies of the adenovirus pIX gene
identified RBP as a transcriptional repressor in in vivo
infection and transfection assays and in in vitro tran-
scription assays using purified RBP protein (Dou et al.,
1994). Hsieh and Hayward (1995) have shown that RBP
acts as a transcriptional repressor by binding to DNA
and inhibiting the transactivation of genes. More re-
cently, RBP was shown to repress nuclear factor-kB
(NF-kB) and CCAAT/enhancer-binding protein-b (C/EBP-
b)-mediated transcription from the interleukin (IL)-6 gene
(Kannabiran et al., 1997). The Drosophila homolog of RBP,
suppressor of Hairless (SuH), acts in Notch receptor
signalling, a pathway that controls cell fate determination
and differentiation (Fortini and Artavanis Tsakonas, 1994),
also suggesting that RBP plays a role in controlling gene
expression. The DNA binding consensus sequence for
RBP has been identified in the promoter region of a
number of cytokines and their receptors, including inter-
feron (IFN)-b, IL-2R-a, granulocyte macrophage-colony
stimulating factor (GM-CSF), IL-6R, and IL-2 (Shirakata et
al., 1996). Indeed, RBP may control the expression of
many cytokines, which in turn modulate cellular prolifer-
ation.
Human IL-1b, located at the q13-q21 locus on chro-
mosome 2, spans a region of 7.5 kb with the coding
region divided into seven exons (Bensi et al., 1987).
There are two structurally distinct IL-1 proteins, a and b,
that have a functional similarity despite a limited homol-
ogy (26%) at the amino acid level (Matsushima et al.,
1985). Both proteins are initially found on the cell surface
before being cleaved to generate soluble cytokines (Mar-
tin and Resch, 1988). IL-1b mediates several physiolog-
ical responses to infections and injuries, including stim-
ulation of thymocyte proliferation, B lymphocyte matura-
tion and proliferation, induction of acute-phase protein
synthesis by hepatocytes, and induction of fever (Din-
arello, 1984; March et al., 1985). In addition, IL-1 has
been shown to influence the growth and differentiation of
a wide range of cell types (reviewed in Dinarello et al.,
1989). There also is evidence showing that IL-1 is syn-
thesised by EBV-transformed B cells (Acres et al., 1987;
Scala et al., 1987) and that IL-1 may function as an
autocrine growth factor of these cells (Gordon et al.,
1986; Scala et al., 1987). Studies by Pistillo et al. (1994)
have also shown that EBV-transformed B cell lines re-
spond with enhanced proliferation to IL-1b. Intracellular
IL-1b was recently demonstrated to act as a specific
endogenous competitive inhibitor of FAS-mediated apop-
tosis in human B lymphoblastoid cells (Tatsuta et al.,
1996), which highlights an important role for the cytokine
in inhibiting apoptosis and therefore enhancing cell sur-
vival and possibly cell proliferation.
Using electrophoretic mobility shift assays (EMSAs),
we demonstrate that the IL-1b promoter contains a func-
tional binding site for RBP. Furthermore, using RT-PCR,
we show that IL-1b is up-regulated in EBV-positive cell
lines, and through the use of cell lines transfected with
the individual EBV latent proteins, we have been able to
show that LMP-1 and EBNAs 2, 3, 4, and 6 could modu-
late IL-1b message.
RESULTS
EBV latent gene expression in cell lines
Cell lysates were prepared from all the cell lines and
electrophoresed on 7.5% SDS–polyacrylamide gels and
electrotransfered onto nitrocellulose membranes. Immu-
noblotting was performed using a previously character-
ised MCr serum (Sculley et al., 1983) to detect EBNAs 1,
2, 3, 4, and 6 (Table 1). The MUTU group I cell line (clone
216) expressed only EBNA 1, whereas the three MUTU
group III cell lines (clones 62, 95, and 148) expressed
EBNAs 1, 2, 3, 4, and 6. The EBV-negative cell lines
BL30A, BL30K, dG75, and BJAB did not show expression
of any EBV latent proteins. All EBV latent antigens were
shown to be expressed in the LCLs and group III BLs.
The panel of BJAB cells transfected with individual latent
proteins all showed expression of the appropriate latent
proteins (Table 1) (Wang et al., 1990). The dG75 cells and
dG75 transfected with either EBNA 3, 4, or 6 or all three
EBNAs have been characterised and reported previously
(Kienzle et al., 1996). Western blotting of these cell lines
showed that the expression levels of the EBNA 3 family
proteins were similar to when they were first character-
ised (Table 1; data not shown). Figure 1 shows the
pattern of EBNA gene expression in the BJAB E2 cells
transfected with the EBNA 3 family genes. These cell
lines expressed EBNA 2, EBNA 1 (resulting from the EBO
vector used for the expression of the EBNA 3 family
genes), and the EBNA 3 proteins.
Intracellular staining for IL-1b protein expression
To determine whether EBV infection of B cells leads to
expression of the cytokine IL-1b, FACScan analysis for
intracellular IL-1b protein was used. Serum was re-
moved from the cells for 3 h before staining to prevent
secretion of the IL-1b as previously demonstrated by
(Rubartelli et al., 1990). Intracellular staining for IL-1b
protein demonstrated that protein was present in a panel
of six different LCLs (Table 2). As expected, the LCLs
stained positive for the B cell marker, CD19, and negative
for the T cell marker, CD4, indicating that the staining
method did not affect the binding properties of the anti-
bodies. To prevent nonspecific binding of PE-conjugated
antibodies to the FcgRII and FcgRIII receptors, antibody-
blocking experiments were performed. The preincuba-
tion of antibodies to these receptors did not affect the
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binding of IL-1b-PE antibody to the LCLs (data not
shown).
IL-1b is up-regulated in LCLs and group III BL cells
compared with group I BL cells
To determine whether EBV infection leads to changes
in IL-1b regulation, the highly sensitive technique of
RT-PCR was used to examine expression levels of IL-1b.
Primers specific for human IL-1b were used to PCR
amplify the IL-1b cDNA. An 800-bp IL-1b DNA fragment
was amplified from EBV-positive BJAB, BL30K, group III
MUTU cells, and the LCL (QIMR-ISM), whereas no prod-
uct was evident in EBV-negative BJAB, BL30A, BL30K,
and MUTU group I cells (Fig. 2A). The PCR-amplified
band was sequenced using the IL-1bR primer to confirm
that it originated from IL-1b. In the EBV-negative BL30
cells, the transition from a resting (BL30A) to activated
(BL30K) B cell phenotype does not lead to alteration in
the level of IL-1b message, indicating the up-regulation
is specific for EBV-latent proteins. These results clearly
show that the level of IL-1b message, as detected by
RT-PCR, is up-regulated in group III BLs and LCLs (ex-
TABLE 1
Cell Line Classification, EBNA Expression, and Reference
Cell line Group/phenotype
EBV latent genes
expressed Reference
BJAB B cell lymphoma (resting phenotype) Nil Klein et al. (1974)
dG75 EBV-negative BL (resting phenotype) Nil Ben Bassat et al.
(1977)
BL30A EBV-negative BL (resting phenotype) Nil Lenoir et al. (1985)
BL30K EBV-negative BL (activated phenotype) Nil Lenoir et al. (1985)
MUTU I clone 216 EBV-positive BL, group I EBNA-1 Gregory et al. (1990)
MUTU III clone 62 EBV-positive BL, group III EBNAs 1-6, LMP-1, 2 Gregory et al. (1990)
MUTU III clone 95 EBV-positive BL, group III EBNAs 1-6, LMP-1, 2 Gregory et al. (1990)
MUTU III clone 148 EBV-positive BL, group III EBNAs 1-6, LMP-1, 2 Gregory et al. (1990)
BJAB/B95.8 LCL EBNAs 1-6, LMP-1, 2 Andersson et al. (1976)
QIMR-ISM LCL EBNAs 1-6, LMP-1, 2 Andersson et al. (1976)
BJAB gpt1 (control) B cell lymphoma Nil Wang et al. (1990)
BJAB E2 (BJAB
U2.15/gpt1)
B cell lymphoma EBNA-2 Wang et al. (1990)
BJAB-LMP-1 B cell lymphoma LMP-1 Wang et al. (1990)
BJAB LMP-1/E2 B cell lymphoma EBNA 2 and LMP-1 Wang et al. (1990)
dG75 EC3 (control) EBV-negative BL EBNA-1 Kienzle et al. (1996)
dG75 E3-F5 EBV-negative BL EBNA-1, 3 Kienzle et al. (1996)
dG75 E6-F11 EBV-negative BL EBNA-1, 6 Kienzle et al. (1996)
dG75 E4 bulk EBV-negative BL EBNA-1, 4 Kienzle et al. (1996)
dG75 E346 bulk EBV-negative BL EBNAs 1, 3, 4, 6 Kienzle et al. (1996)
FIG. 1. Western blot of the BJAB E2 cells cotransfected with expres-
sion vectors encoding the EBNA 3 family genes: EBNA 3 (EBO-E3),
EBNA 4 (EBO-E4), EBNA 6 (EBO-E6), and EBNAs 3, 4, and 6 (EBO-E346).
The BJAB E2 cells transfected with the vector alone (EBO) are also
shown. Total cell lysates from each of the cell lines were prepared and
run on 7.5% polyacrylamide gel before transfer onto membrane and
probed with MCr human sera. The positions of EBNAs 2, 3, 4, and 6 are
indicated by the arrows.
TABLE 2
Intracellular Staining of IL-1b Protein in a Panel of LCLs
Cell line Backgrounda IL-1b-PEb CD19-FITCb CD4-PEb
LC B95.8 LCL 4.45 14.67 20.88 5.37
RC WIL LCL 5.06 21.89 28.05 9.21
AF WIL LCL 3.23 66.95 19.15 2.39
CS B95.8 LCL 4.58 74.15 20.15 4.54
LC AG876 LCL 4.27 64.77 6.75
BM WIL LCL 7.06 64.78
Note. The table shows the panel of LCLs that were examined and the
mean fluorescence intensity of each sample.
a Mean fluorescence intensity of cells only.
b Mean fluorescence intensity of cells stained with various labeled
antibodies.
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pressing the full set of EBV-latent antigens) in compari-
son to group I BLs expressing only EBNA 1.
Up-regulation of IL-1b by the EBNAs
To identify which of the EBNA proteins may have been
responsible for the up-regulation of IL-1b, RT-PCR was
again used to quantify IL-1b cDNA in a panel of cell lines
stably transfected with individual EBNA genes. b2-Micro-
globulin was also amplified from each of the cell lines
using 22 cycles of PCR amplification to standardise load-
ings of the samples. The RT-PCR results shown are from
one transfectant that is representative of the results
obtained using three individual transfectants for each
EBV gene analysed. Using 35 cycles of PCR, an 800-bp
fragment corresponding to IL-1b was detected in dG75
cells transfected with either EBNA 3, 4, 6, or all three
EBNAs, whereas dG75, dG75 EC3 (control vector trans-
fected cells expressing EBNA 1), and the water control
were negative (Fig. 3). Expression of EBNA 3 or 6 alone
led to greater increases in IL-1b message than EBNA 4
or expression of all EBNA 3 family proteins. BJAB cell
lines transfected with either or both EBNA 2 and LMP-1
also showed increased levels of IL-1b (Fig. 4). These
results indicate that IL-1b could be up-regulated by E3,
E4, and E6 in dG75 BL cells and by EBNA 2 and LMP-1
in the B lymphoma cell line BJAB. BJAB/E2 cells cotrans-
fected with the EBNA 3 family genes showed varying
levels of IL-1b message (Fig. 5). BJAB/E2, BJAB/E2 co-
transfected with the control vector EBO-pLPP (express-
ing EBNA 1), or EBO-E4 showed similar levels of IL-1b,
whereas BJAB/E2 cells cotransfected with EBO-E6, EBO-
E3, or EBO-E346 had reduced levels of the IL-1b in
comparison to the BJAB/E2-EBO-pLPP (EBNA 1-express-
ing) control cells. These results indicate that the high
level of IL-1b message in the BJAB/E2 cells can be
down-regulated by coexpression of EBNA 3 or 6.
FIG. 2. RT-PCR amplification of IL-1b and b2 cDNAs from a panel of
group I and III BL cell lines (BJAB1, BJAB2, BL30A, BL30K, a selection
of MUTU I and III cells, and an LCL QIMR-ISM). The upper panel shows
the results from PCR amplification using IL-1b-specific primers,
whereas the lower panel shows the result for the b2-specific primers.
Markers and water control lanes are shown.
FIG. 3. RT-PCR amplification of IL-1b and b2 cDNAs from dG75 cells
transfected with the individual EBV genes: EBNA 3 (dG75 E3-F5), EBNA
4 (dG75 E4), or EBNA 6 (dG75 E6) or all three EBNA 3 family genes:
dG75 E3,4,6. As controls, dG75 cells and dG75 cells transfected with
the vector alone (dG75 EC3) are as shown. The upper panel shows the
results from PCR amplification using IL-1b-specific primers, and the
lower panel shows the results from PCR amplification using b2-specific
primers. The water controls, markers, and positive control cells (QIMR-
ISM LCL) are as shown.
FIG. 4. RT-PCR amplification of IL-1b and b2 cDNAs from BJAB2
cells transfected with the following EBV latent genes: EBNA 2 (BJAB
E2), LMP-1 (BJAB LMP-1), a combination of LMP-1 and EBNA 2 (BJAB
E2/LMP-1), and vector control cells (BJAB gpt1). BJAB cells infected with
EBV (BJAB1) and without (BJAB2) and water controls are as shown.
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RBP binds to its DNA recognition site in the IL-1b
promoter region
Because the EBNA 3 family genes and EBNA 2 appear
to be able to modulate the level of IL-1b message, it is
possible that these proteins exert this effect via interac-
tion with the DNA binding protein RBP. Analysis of the
IL-1b promoter region revealed the presence of a single
RBP DNA consensus sequence at position 2298 to
2292. To determine whether this RBP site was func-
tional, complementary synthetic oligonucleotides, corre-
sponding to this RBP consensus sequence, were pre-
pared, annealed, and used in gel shift analyses. Nuclear
extracts prepared from dG75 cells were incubated with
32P-labeled probe, and binding complexes were anal-
ysed on polyacrylamide gels (Fig. 6). These results show
that two complexes were formed when 5 mg of dG75
nuclear extract was incubated with the IL-1b probe (Fig.
6, lane 2). The subsequent addition of anti-RBP mono-
clonal antibody led to the lower complex being super-
shifted, demonstrating the presence of RBP in this com-
plex (Fig. 6, lane 3). The addition of an irrelevant antibody
(anti-E6) led to no change in the binding complex (Fig. 6,
lane 4). To demonstrate the specificity of this lower
complex for the RBP DNA consensus site, binding reac-
tions were performed in the presence of unlabelled
probe. The addition of excess unlabelled probe led to
abolition of the binding of the RBP protein to the radio-
labelled probe (Fig. 6, lane 5). Competition experiments
also were performed using a probe with six of seven
bases in the RBP DNA consensus site mutated (MUT).
The RBP binding complex was not altered by addition of
this mutated probe (Fig. 6, lane 6). As an additional
control for RBP binding to the IL-1b promoter sequence,
a probe was prepared in which the first two bases of the
RBP site were mutated (RBP mut). The addition of nu-
clear extract to this probe did not result in binding of the
lower complex RBP (Fig. 6, lane 9), indicating that inter-
action of RBP to its DNA consensus sequence requires
the presence of the first two bases in the DNA site.
Competition of the IL-1b probe with excess RBP mut
probe resulted in no change in the RBP binding complex,
whereas the weaker upper band was abolished (Fig. 6,
lane 7). These results demonstrate that RBP is able to
specifically interact with the RBP DNA consensus se-
quence present in the IL-1b promoter.
As well as the RBP binding complex, a second higher
binding complex was also observed (Fig. 6). This com-
plex was specific for the probe as the level of binding
decreased after the addition of excess unlabelled probe
(Fig. 6, lane 5), and it did not contain RBP because it
could not be supershifted by the addition of anti-RBP
antibody (Fig. 6, lane 3). To determine whether the upper
complex was due to NF-kB binding, EMSA was per-
formed using antibodies specific for NF-kB in supershift-
ing experiments (Fig. 7). The addition of dG75 extract to
the IL-1b probe led to the formation of the expected
complexes (lane 2), with the lower complex being due to
RBP, as the subsequent addition of anti-RBP led to a
complete shift in this binding complex (lane 3). However,
the addition of anti-p50 NF-kB (lane 4) or anti-p65 NF-kB
(lane 5) antibodies failed to supershift either of the bind-
ing complexes, indicating that the p50 and p65 subunits
of NF-kB were not binding to the IL-1b promoter. The
FIG. 6. EMSA for RBP activity in dG75 nuclear extracts using the
IL-1b probe (59-TCTTCTAACGTGGGAAAATCCAGT-39) (RBP DNA bind-
ing site underlined) and RBP Mut probe that has the RBP DNA recog-
nition sequence mutated in the first two bases (see double underlined
bases) (59-TCTTCTAACACGGGAAAATCCAGT-39). The lanes show the
presence of nuclear extract (1 or 2), addition of RBP antibody (RBP
Ab), addition of an irrelevant antibody (anti-E6), competition with 100-
fold excess unlabelled IL-1b probe (IL-1b), competition with a probe in
which the IL-1b consensus sequences have been mutated (Mut; 59-
TCTTCTAACGGATCGTAGTCCAGT-39), and competition with a probe
with the first two bases of the RBP site mutated (RBP mut; 59-TCT-
TCTAACACGGGAAAATCCAGT-39). Mutated bases are double under-
lined. The positions of RBP and the RBP supershifted complexes are
shown by arrows.
FIG. 5. RT-PCR amplification of IL-1b cDNAs from BJAB E2 cells
cotransfected with the individual EBNA 3 genes: EBNA 3 (EBO-E3),
EBNA 4 (EBO-E4), or EBNA 6 (EBO-E6) or all three EBNA 3 family genes
(EBO-E3,4,6). In addition, the BJAB-EBNA2 (BJAB-E2) and the BJAB-
EBNA2 cells transfected with the vector alone (EBO-pLPP) are shown.
The lanes with water control and markers are as shown. The upper and
lower panel shows the results from PCR amplification using IL-1b-
specific primers using 40 cycles of amplification.
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addition of control antibody had no effect on either of the
binding complexes (lane 6). The results confirm that RBP
is responsible for the lower binding complex and sug-
gest that the upper complex is not due to NF-kB. An
earlier study has identified another DNA binding protein,
NF-bD, that binds to the 2300 region of the IL-1b pro-
moter (Monks et al., 1994). Therefore, the upper binding
complex is most likely due to binding by NF-bD.
NF-kB binding activity in dG75 nuclear extracts
One possible reason for the inability of NF-kB to bind
to the IL-1b probe was a lack of activated NF-kB in the
dG75 nuclear extracts. Therefore, to establish whether
this was the case, a probe containing the NF-kB consen-
sus sequence was used in EMSA (Fig. 8). After the
addition of the dG75 nuclear extract to the NF-kB probe,
two binding complexes were observed (lane 2). To es-
tablish the identity of the binding complexes, supershift-
ing was performed with anti-p65 NF-kB (lane 3) and
anti-p50 NF-kB (lane 4) subunit antibodies. Shifting of the
upper binding complex was observed when either the
p65 NF-kB antibody (indicated by the asterix) or the p50
NF-kB antibody was used indicating the presence of
NF-kB in this complex. In addition, the upper complex
was shown to be specific for the NF-kB probe as com-
petition with 100-fold excess of unlabelled NF-kB probe
led to its abolition (lane 6) and the addition of cold IL-1
mut (IL-1b probe with the NF-kB and RBP sites mutated)
probe failed to complete out the upper complex (lane 9).
The inability of either the IL-1b probe or the RBP mut
probe (IL-1b with the RBP site mutated) to compete out
the upper complex (lanes 7 and 8) suggested that NF-kB
may not be able to bind to the IL-1b–NF-kB binding site.
The addition of anti-RBP antibody (lane 5) led to the
lower binding complex being supershifted, demonstrat-
ing the presence of RBP in this complex. On close ex-
amination of this NF-kB probe, the DNA consensus bind-
ing site for the RBP protein was identified on the com-
plementary strand. This explained why the IL-1b probe
(which can bind RBP) competed out the lower binding
complex, whereas the IL-1 mut and RBP mut probes
were unable to compete. These results demonstrated
that dG75 nuclear extracts contained activated NF-kB
and suggested that RBP and NF-bD (Monks et al., 1994)
bind to the 2300 region of the IL-1b promoter in prefer-
ence to NF-kB.
Activation of NF-kB by EBV and expression of LMP-1
To demonstrate that activation of NF-kB was occurring
in EBV-transformed cells and LMP-1-transfected cells,
EMSA was performed on nuclear extracts using a probe
containing the classic NF-kB DNA consensus sequence.
Two binding complexes were observed in the BJAB cells
transfected with the control vector (Fig. 9, lane 2), BJAB
cells transfected with LMP-1 (lane 3), and EBV-trans-
formed cells CS-B95.8 LCL (lane 7). Both complexes
were specific for the NF-kB probe, as competition with
100-fold excess of the NF-kB probe abolished both bind-
ing complexes, whereas competition with an irrelevant
probe or probe containing a mutated NF-kB site had no
effect on the complexes (lanes 4–6, respectively, for
FIG. 8. EMSA for NF-kB activity in dG75 nuclear extracts using the
NF-kB probe (59-AGTTGAGGGGACTTTCCCAGGC). The lanes show the
presence of nuclear extract (1 or 2), addition of anti-p50 NF-kB
antibody (anti-p65 NF-kB), addition of anti-p65 NF-kB antibody (anti-p50
NF-kB), and addition of anti-RBP antibody (anti-RBP). Competition ex-
periments performed with 100-fold excess unlabelled NF-kB (NF-kB),
100-fold excess of unlabelled IL-1b (IL-1b), competition with 100-fold
excess of unlabelled RBP mutant (RBP mut; first two bases in the RBP
DNA consensus site are mutated), and competition with 100-fold ex-
cess of unlabelled IL-1 mut (IL-1 mut; RBP and NF-kB consensus
sequences have been mutated). The positions of RBP, NF-kB, and
supershifted complexes are shown by the arrows.
FIG. 7. EMSA for RBP and NF-kB activity in dG75 nuclear extracts
using the IL-1b probe (59-TCTTCTAACGTGGGAAAATCCAGT). The
lanes show the presence of nuclear extract (1 or 2), addition of
anti-RBP antibody (anti-RBP), addition of an control antibody (control
Ab), addition of anti-p50 NF-kB antibody, and addition of anti-p65 NF-kB
antibody. The positions of RBP, RBP supershifted and upper complexes
are shown by the arrows.
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BJAB-LMP1 and lanes 8–10, respectively, for CS-B95.8).
In BJAB cells transfected with LMP-1 and in the CS-B95.8
LCL, the upper NF-kB binding complex was considerably
stronger than that in the BJAB control transfected cells.
These results demonstrate that NF-kB is up-regulated in
EBV-transformed cells and LMP-1-transfected BJAB cells
in comparison to the BJAB control cells.
NF-kB binding to the 2300 region of the IL-1b
promoter
Previous studies examining the IL-1b promoter have
shown that on activation, NF-kB is capable of binding
and up-regulating IL-1b expression (Cogswell et al.,
1994; Hiscott et al., 1993). To determine whether NF-kB
was capable of binding to the 2300 region of the IL-1b
promoter, EMSA was performed using nuclear extracts
from an LCL, QIMR-CS/B95.8. LCLs have been shown to
contain high levels of activated NF-kB (Herrero et al.,
1995) and were used in EMSA with the IL-1b probe. This
provided the opportunity to establish whether RBP, NF-
kB, and NF-bD are capable of independently binding to
the IL-1b promoter. After incubation of nuclear extract
with the IL-1b probe, three binding complexes were
observed (Fig. 10, lane 2). The addition of anti-RBP anti-
body led to the bottom complex being completely super-
shifted (lane 3), confirming that this complex was due to
RBP binding. The top binding complex contained the p50
and p65 subunits of NF-kB as supershifting with the
subunit specific antibodies led to removal of the complex
(lanes 5 and 6). The addition of an irrelevant antibody did
not affect any of the binding complexes (lane 4). These
results confirmed that NF-kB was capable of binding to
the IL-1b promoter in B cell extracts that contained high
levels of activated NF-kB. The results demonstrate that
RBP, NF-kB, and the other binding protein, NF-bD, bind
independently to the IL-1b promoter.
EBNAs 3 and 6 led to a decrease in the level of
binding of RBP to its consensus binding sequence
EBNAs 3 and 6 have previously been shown to bind
RBP and prevent it from binding to its DNA recognition
site (Robertson et al., 1996). To determine whether this
may be the mechanism by which EBNAs 3 and 6 up-
regulate IL-1b, gel shift analyses were performed in the
presence of baculovirus-purified EBNA 3 and 6 proteins
(Fig. 11). The addition of purified EBNA 3 (lane 4) or EBNA
6 (lane 5) resulted in a decrease in the binding of RBP to
the IL-1b probe (lane 2). These results confirm the find-
ings of Robertson et al. (1996) that the EBNA 3 family
proteins can disrupt the binding of RBP to its consensus
binding site and suggest that EBNAs 3 and 6 may be
up-regulating IL-1b via interaction with RBP.
DISCUSSION
IL-1 is a multifunctional cytokine that plays important
roles in haematopoietic cell development (Bagby, 1989)
and the host response to bacterial and viral infections
(Dinarello, 1991). The IL-1b promoter has been exten-
sively studied by a number of groups, and many tran-
scriptional regulatory elements have been identified
within the promoter. Cogswell et al. (1994) identified
three NF-kB regions: one between 22800 to 22720, and
the other two located between 2512 and 2133 bp of the
IL-1b promoter. In addition, a C/EBP/NF-IL-6 site has
FIG. 10. EMSA for NF-kB binding activity in an LCL nuclear extract
using the wild-type IL-1b probe. Addition of LCL nuclear extract is
indicated by the 1 or 2. The lanes show the presence of antibodies
against RBP (anti-RBP), p50 NF-kB (anti-p50 NF-kB), anti-p65 NF-kB
(anti-p65 NF-kB), and control (control Ab). The positions of the RBP
(lower complex), NF-kB (upper complex), middle complex, and super-
shifted bands are shown by the arrows.
FIG. 9. EMSA for NF-kB activity in nuclear extracts from BJAB cells,
BJAB cells transfected with LMP-1 (BJAB-LMP1), and CS B95.8 LCL
(LCL) using a probe containing a classic NF-kB consensus sequence.
The positions of the NF-kB complexes are indicated by the arrows. The
lanes show the addition of nuclear extract (1 or 2) and 100-fold excess
cold competitors.
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been located between 22896 and 22864, a NF-b1 site
has been between 22761 and 22753 bp (Shirakawa et
al., 1993), and a cAMP response element has been
located between 22761 and 22753 (Lorenz et al., 1995).
Inducible expression from the IL-1b promoter has also
been linked to the presence of AP-1 and Spi-1/PU.1
binding sites within the promoter region (Kominato et al.,
1995). This study is the first to report the presence of
another regulatory element within the IL-1b promoter,
RBP, which could allow modulation of expression from
this promoter. RBP has been recognised as a DNA bind-
ing protein that acts as a transcriptional repressor in
mammalian systems. In addition, we demonstrated that
in unstimulated dG75 cells, RBP and NF-bD, which com-
pete for binding, preferentially bind to the promoter over
NF-kB. In the presence of activated NF-kB, all three DNA
binding proteins were able to bind to the IL-1b promoter
in B cell extracts. Studies on the IL-6 promoter have
conclusively demonstrated that RBP-Jk can transcription-
ally repress coactivation of the IL-6 gene by the tran-
scription factors C/EBP-b and NF-kB (Kannabiran et al.,
1997). We now demonstrate that the IL-1b promoter,
similar to the IL-6 promoter (Plaisance et al., 1997), con-
tains overlapping RBP and NF-kB sites that are likely to
play a role in the regulation of IL-1b transcription.
NF-kB, a ubiquitous transcription factor, has been
shown to activate the expression of a number of genes
responsible for cellular activation and proliferation (re-
viewed in Baeuerle and Henkel, 1994). NF-kB in its acti-
vated form consists of heterodimers or homodimers
composed of different subunits and binds to the DNA
consensus sequence 59-GGGRHTYYCC (Lenardo and
Baltimore, 1989). Initially, NF-kB is localised to the cyto-
plasm in an inactive form complexed with IkB. After
activation, which can occur through a wide variety of
stimuli, NF-kB is released and then is translocated to the
nucleus, where it interacts with its DNA consensus se-
quences, leading to transcriptional activation. Within the
immune system, NF-kB appears to be extensively used
(1) due to its ability to respond rapidly to external signals,
and (2) once activated, it functions as a potent transcrip-
tional activator.
Characterisation of the IL-1b promoter RBP site
showed that the DNA consensus sequence was func-
tional (Figs. 6, 7, and 10) and that it overlapped with a
previously characterised NF-kB DNA binding site and lay
adjacent to a NF-bD binding site (Cogswell et al., 1994;
Hiscott et al., 1993). The gel shift analyses clearly
showed the formation of only two complexes after incu-
bation of the IL-1b probe with dG75 nuclear extract: one
due to RBP binding, and the other higher complex pos-
sibly due to NF-bD binding (Figs. 6 and 7). The RBP
binding complex was displaced only after the addition of
probes specific for the RBP binding site and not after
competition with probes that have bases mutated within
the RBP DNA consensus site. The consequences of the
overlapping RBP and NF-kB DNA binding sites on the
IL-1b promoter is, however, unknown and requires fur-
ther analysis.
Responsiveness to phorbol ester, poly(rI-rC), Sendai
virus infection, and IL-1b has been mapped to the 2300
region of the IL-1b promoter (Hiscott et al., 1993). Dele-
tion of this region containing the IL-1b NF-kB site re-
duced the ability of the IL-1b promoter to direct reporter
gene expression in transient transfection assays
(Shirakawa et al., 1993). Given that a DNA binding site for
RBP, a transcriptional repressor, and NF-bD overlap with
the NF-kB site, these proteins may act as negative reg-
ulators of IL-1b transcription. Because dG75 cells do not
show expression of IL-1b (Fig. 3) and RBP and NF-bD
preferentially bind to the 2300 region of the promoter
(Figs. 6 and 7), this may be a mechanism whereby low
levels of nuclear NF-kB can be prevented from activating
IL-1b expression. A number of other promoters were
identified by scanning the GenBank databases that con-
tain overlapping NF-kB and NF-bD sites, suggesting that
this may be a common mechanism whereby gene ex-
pression is controlled.
Recently, Kannabiran et al. (1997) identified an RBP
site that overlaps with the binding site for NF-kB that
mediates transcriptional activation in the IL-6 promoter.
The study demonstrated that the position of the RBP site
was critical in mediating the repression and that RBP
bound adjacent to NF-kB hindering gene activation. An-
other study went on to show that the presence of the RBP
protein was responsible for the low basal levels of IL-6
promoter activity and suggested that RBP partially
blocked access of NF-kB complexes (Plaisance et al.,
1997). This was the first example of the significance of
overlapping sites of the transcriptional activator NF-kB
and the transcriptional repressor protein RBP. A similar
FIG. 11. EMSA for RBP activity in dG75 nuclear extracts after the
addition of purified baculovirus EBNA 3 and 6 proteins using the IL-1b
probe (59-TCTTCTAACGTGGGAAAATCCAGT-39). The positions of the
RBP and RBP supershifted complexes are indicated by the position of
the arrows. The lanes show the addition of nuclear extract (1 or 2),
RBP antibody (RBP Ab), and purified baculovirus EBNA 3 (E3 protein)
and EBNA 6 (E3 protein).
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scenario could be predicted for gene expression from
the IL-1b promoter, whereby a cell can finitely control the
expression of cytokines capable of regulating cell acti-
vation and proliferation.
Because EBV-transformed B cell lines show enhanced
proliferation to IL-1b (Pistillo et al., 1994; Scala et al.,
1987) and FAS-mediated apoptosis in B cell lines is
inhibited by IL-1b, we investigated the possibility that
IL-1b was up-regulated in EBV-infected cells. Earlier
studies have detected IL-1b message and synthesis
using biological assays in a number of EBV-transformed
B cell lines (Acres et al., 1987; Scala et al., 1987). Herein,
we use FACScan analysis to show expression of IL-1b in
a panel of LCLs (Table 2). Comparison of the different
LCLs indicated that levels of IL-1b were fairly consistent
and that the whole population of cells expressed the
cytokine. Of particular interest, the levels of intracellular
IL-1b did not substantially increase after serum removal
(data not shown), suggesting that the cytokine is not
secreted but rather remains membrane bound within the
B cells. Using RT-PCR analyses, we demonstrated an
increase in IL-1b message in LCLs and group III BLs,
expressing the full set of EBV latent genes, in compari-
son to group I BLs, which expressed only EBNA 1 (Fig. 2).
The use of dG75 and BJAB cells, expressing individual
EBV latent proteins, demonstrated that the expression of
EBNAs 2, 3, 4, or 6 or LMP-1, individually, resulted in an
increase in the level of IL-1b message (Figs. 3 and 4).
However, cotransfection of EBNAs 3 or 6 or EBNAs 3, 4,
and 6 together into BJAB/E2 cells led to down-regulation
of IL-1b message (Fig. 5), a result expected if regulation
of the IL-1b message by the EBNAs was occurring via
their interaction with RBP (Krauer et al., 1996; Robertson
et al., 1996; Young et al., 1997; Zhao et al., 1996). EBNA 2
has been shown to transactivate gene expression via its
interaction with RBP, whereas EBNAs 3 and 6 appear to
be able to displace EBNA 2 from RBP and prevent RBP
from binding to its DNA recognition site and hence pre-
vent EBNA 2-mediated transactivation (Krauer et al.,
1996; Robertson et al., 1996; Young et al., 1997; Zhao et
al., 1996). Using gel shift and supershift analyses, we
have shown that RBP binds to its recognition sequence
within the IL-1b promoter and that on the addition of
purified EBNA 3 and EBNA 6 proteins, the binding of RBP
to its DNA binding site was prevented (Fig. 11). These
results suggest that regulation of this promoter by the
EBNAs is similar to that described for LMP-1 and the
viral terminal protein (Le Roux et al., 1994; Robertson et
al., 1995).
An important observation from this study is that IL-1b
expression can be differentially modulated by the indi-
vidual EBNA proteins. EBNAs 3 and 6 are both capable of
strongly increasing IL-1b message and inhibiting EBNA
2-mediated transactivation, whereas EBNA 4 has only
minimal or no effects. This result highlights a difference
among the EBNA 3 family proteins and could reflect the
previously characterised differences in the binding affin-
ities of the EBNAs for RBP (Krauer et al., 1996).
Because the IL-1b promoter contains a number of
NF-kB sites that positively regulate transcription, it is
likely that the EBV latent protein LMP-1 also influences
IL-1b gene expression through NF-kB activation (Herrero
et al., 1995). This would be in agreement with (1) the
RT-PCR results obtained from BJAB cells transfected with
LMP-1 (Fig. 4), where there was an increase in the level
of IL-1b message in comparison to BJAB cells, and (2)
with the EMSA showing increased levels of NF-kB in
LMP-1-transfected BJAB cells compared with BJAB vec-
tor control cells (Fig. 9). It is likely that regulation of IL-1b
transcription by EBV involves a number of the latent
proteins: LMP-1 through NF-kB and EBNAs 2, 3, 4, and 6
via their interaction with RBP. In LCLs and group III BLs,
IL-1b message is always up-regulated, suggesting that
the net effect of all the EBV proteins is increased gene
expression. These observations led to the conclusion
that IL-1b may play a role in EBV transformation of B
cells, especially considering that the virus encodes five
latent proteins whose cooperative effect is to up-regulate
IL-1b expression. The actual stoichiometry of the in vivo
interactions among the EBNAs, LMP-1, NF-kB, Notch,
and RBP requires considerably more investigation to
understand how these proteins cooperate to regulate
cellular gene expression.
The involvement of IL-1b in the competitive inhibition
of apoptosis signalled through the IL-1b-converting en-
zyme (ICE) pathway provides an important role for this
cytokine in cell survival. That EBV encodes viral proteins
that control the expression of IL-1b would suggest that
the virus uses an important survival pathway. Moreover,
the virus has devised a strategy whereby the expression
of IL-1b is maintained, again suggesting that this protein
may play a role in enhancing proliferation or maintaining
EBV transformation. Maintenance of the intracellular lev-
els of IL-1b after EBV transformation could lead to the
inhibition of apoptosis after virus infection and therefore
enable survival of virus-infected cells. Combined with the
previously reported proliferative activity of IL-1b on LCLs,
it seems the EBV uses a cytokine that could enhance cell
survival and proliferation.
So far, a broad spectrum of other cellular promoters
have been identified that contain RBP DNA consensus
sites, including IL-6 (Kannabiran et al., 1997), IL-6 recep-
tor (Grossman et al., 1994), IFN-g, IL-2, IL-2R, and GM-
CSF (Shirakata et al., 1996). In Drosophila melanogaster,
a homozygous null mutation in RBP leads to death during
embryonic development, highlighting the importance of
this gene in cellular growth and differentiation (Oka et al.,
1995). EBV encodes four gene products that can poten-
tially regulate and control gene expression through their
interaction with RBP, which suggests that exquisite con-
trol of the expression of these genes is necessary for the
maintenance of transformation or the activated cellular
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state. To fully understand how EBV manipulates normal
cellular control mechanisms to drive cells to immortal-
isation require a more detailed knowledge of the inter-
action of the EBNAs with RBP and their effect on tran-
scription of cellular genes.
MATERIALS AND METHODS
Cell lines and maintenance
All cell lines (see Table 1) were maintained in RPMI
1640 supplemented with 10% FSC, benzylpenicillin (0.7
mg/ml), and streptomycin (1 mg/ml) at 37°C in 5% CO2
atmosphere. When culturing the dG75-transfected cell
lines, 500 mg/ml hygromycin B (Boehringer Mannheim)
was added. For the BJAB-transfected cell lines (BJAB/E2),
3 mg/ml mycophenolic acid and 3 mg/ml G418 (Sigma
Chemical) were added. The BJAB/E2 cells, cotransfected
with the EBO-pLPP vectors containing the EBNA 3 family
genes (Kienzle et al., 1996), were also supplemented with
500 mg/ml hygromycin B. The BJAB gpt1 control trans-
fectants were supplemented with 3 mg/ml mycophenolic
acid only.
Transfection of cell lines
BJAB/E2 cells (Wang et al., 1990) were transfected by
electroporation with the EBO-pLPP vectors expressing
the individual EBNA 3 family genes (Kienzle et al., 1996).
Briefly, a total of 5 3 106 BJAB E2 cells (log phase growth)
were resuspended in 0.4 ml of RPMI 1640 with 10% FCS
and placed in a Gene Pulser cuvette (BioRad Laborato-
ries). DNA was introduced into cells by electroporation in
a BioRad Gene Pulser with 0.23 kV at 960 mF (time
constant, ;40 ms). After electroporation, cells were in-
cubated on ice for 5 min before resuspension in 6 ml of
RPMI 1640 with 10% FCS. After 48 h, the BJAB E2-
transfected cells were selected in media containing 500
mg/ml hygromycin B to isolate cells expressing the EBNA
3 family genes. Surviving heterogeneous cultures were
maintained in media containing hygromycin B.
Immunoblotting
Protein extracts from 2 3 105 cells were electropho-
resed on 7.5% SDS–polyacrylamide gels (Sambrook et
al., 1989) and electrotransferred onto Hybond-ECL nitro-
cellulose (Amersham). The membrane was blocked for
1 h at room temperature with Blotto (5% skim milk in
PBS). Expression of the EBNA 1, 2, 3, 4, and 6 proteins
was detected by incubation with human serum (MCr
serum) (Sculley et al., 1984) diluted 1:200 in Blotto. The
filters was then subjected to three washes (10 min) with
PBS-Tween (PBS plus 0.05% Tween 20). The nitrocellu-
lose filters were incubated for 1 h with 1:1000 dilution
sheep anti-human IgG HRP (Silenus). After three 10-min
washes in PBS-Tween, EBV-specific proteins were visu-
alised using the ECL Western blotting detection system
(Amersham).
Isolation of total RNA
Cells (5 3 106) were lysed by the addition of 1 ml Total
RNA Isolation Reagent (14 M solution of guanidine salts
and urea) (Advanced Biotechnologies) and then pipetted
up and down. After homogenization, the mixture was
then stored for 5 min at 4°C to permit the complete
dissociation of nucleoprotein complexes. After the addi-
tion of 200 ml of chloroform/ml of RNA reagent, the
samples were vortexed lightly and then centrifuged at
13,000 g in a microfuge at 4°C for 15 min. The aqueous
phase was transferred to a new tube containing an equal
volume of isopropanol and left at 4°C for 10 min. The
samples were again centrifuged at 13,000 g for 10 min,
the supernatant was removed, and the RNA pellet was
washed twice with 75% ethanol. The RNA pellet was
air-dried and resuspended in 50 ml of DEPC-treated
RNase-free H2O.
cDNA synthesis
Total RNA was reverse transcribed into first-strand
cDNA using SuperScript II enzyme according to the man-
ufacturer’s guidelines (Life Technologies). Briefly, 20 ng
of oligo(dT) primers and 1 mg of RNA (in a total volume of
12 ml in a nuclease-free tube) were incubated at 70°C for
10 min and then chilled on ice. After a 5-s centrifugation
(5000 g), 8 ml of a mastermix (142.8 mM Tris–HCl, pH 8.3,
214.3 mM KCl, 8.57 mM MgCl2, 30 mM DTT, and 1.4 mM
concentration of each dNTP) was added, and the solu-
tions were incubated at 42°C for 2 min. Then, 1 ml of
SuperScriptII was added and incubated at 42°C for 50
min.
RT-PCR detection of IL-1b expression
The level of IL-1b mRNA expression in various cell
lines was determined using RT-PCR. A final volume of 20
ml contained PCR buffer (10 mM Tris–HCl, pH 8.3, 50 mM
KCl), 1.5 mM MgCl2, 1 unit of AmpliTaq DNA polymerase,
2 mM IL-1bF primer (59-ATG GCA GAA GTA CCT AAG
CTC GC-39), 2 mM IL-1bR primer (ACA CAA ATT GCA
TGG TGA AGT CAG TT-39), 200 mM concentration of each
dNTP, and 1 mg of cDNA (Lagoo-Deenadaylan et al.,
1993). The mixture was amplified on a 9600 Perkin-Elmer
GeneAmp PCR system, using the following conditions:
82°C for 2 min, 94°C for 20 s, 60°C for 40 s, 72°C for 40 s
for 35 or 40 cycles, and an extension at 72°C for 5 min.
The IL-1 primers span five large introns and therefore
leads to the amplification of cDNA alone. The PCR prod-
uct of ;800 bp was analysed on a 1% agarose gel in TAE
buffer containing ethidium bromide. The conditions used
to determine the expression of b2-microglobulin were
identical to those used for IL-1b except for the substitu-
tion of the b2F primer (59-CCC CCA CTG AAA AAG ATG
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AG-39) and b2R primer (TCA CTC AAT CCA AAT GCG
GC-39). Amplification of the b2-microglobulin product
was performed for only 22 cycles to ensure that amplifi-
cation was nonsaturating. In addition, the b2-microglobu-
lin product was used to standardise loadings of the
samples.
Intracellular staining for IL-1b
Cells were harvested and washed in wash buffer [PBS
consisting of 1% (v/v) FCS and 0.1% (w/v) sodium azide]
before fixation for 10 min at 4°C in buffer F (4% parafor-
maldehyde in PBS). The cells were washed twice in
wash buffer and stored ready for later use. Cells (1 3
106) then were washed twice in 1 ml of permeabilisation
buffer [PBS consisting of 1% (v/v) FCS, 0.1% (w/v) sodium
azide, and 0.1% (w/v) saponin] before resuspension in 40
ml of permeabilisation buffer. Anti-IL-1b-PE- (Biosource),
anti-CD4-PE-, and anti-CD19-FITC- (Becton-Dickenson)
conjugated antibodies were then added to the cells and
incubated for 30 min at 4°C. To prevent nonspecific
binding of PE-conjugated antibodies, anti-FCgRII and
FCgRIII antibodies were added before the IL-1b and CD4
antibodies. Before FACScan analysis, the cells were
washed three times in 1 ml of permeabilisation buffer
and then resuspended in PBS.
Cell extracts and gel retardation assays
Extracts were prepared using a previously described
method (Digman et al., 1983). Briefly, 2 3 107 cells were
washed in PBS and resuspended in 1 ml of cold buffer A
[10 mM HEPES, pH 8, 50 mM NaCl, 500 mM sucrose, 1
mM EDTA, 0.25 mM EGTA, 0.6 mM spermidine HCl, 0.5%
(v/v) Triton X-100, 1 mM PMSF, and 7 mM b-mercapto-
ethanol]. The cells then were homogenised in a Dounce
homogeniser using 15 strokes and transferred to a fresh
tube. After centrifugation (650 g for 10 min at 4°C), the
supernatant (cytoplasmic extract) was collected. The pel-
let then was resuspended in 300 ml of buffer B [10 mM
HEPES, pH 8, 400 mM NaCl, 25% (v/v) glycerol, 0.1 mM
EDTA, 0.1 mM EGTA, 0.6 mM spermidine HCl, 1 mM
PMSF, and 7 mM b-mercaptoethanol] and incubated on
a rocking platform at 4°C for 40 min. After centrifugation
(1100 g for 10 min at 4°C), the supernatant (nuclear
extract) was collected. Gel retardation assays were per-
formed using the Bandshift kit (Pharmacia) according to
the manufacturer’s instructions. Briefly, the binding reac-
tions were performed in 10 mM Tris–HCl, pH 7.5, 50 mM
NaCl, 0.5 mM DTT, 1.5 mM EDTA, 1 mM MgCl2, 4%
glycerol, and 0.5 mg of poly(dI-dC)/poly(dI-dC). Competi-
tors or antibodies were incubated with the nuclear pro-
tein extracts on ice before the addition of the radiola-
beled probes. The anti-RBP antibody was supplied by
Prof. T. Honjo and has been described previously (Sakai
et al., 1995). The NF-kB antibodies directed against the
p50 and p65 subunits were supplied by Santa Cruz
Biotechnology (Santa Cruz, CA). The 32P-end-labeled
double-stranded oligonucleotides and PCR-generated
fragments were used as probes. The sequence of the
probes used in this study were as shown in Table 3.
Baculovirus production of EBNA and EBNA 6 proteins
EBNA 3 cDNA (BamHI restricted) was subcloned from
EBO-E3 (Kienzle et al., 1996) and ligated directly into
pBlueBacHis (InVitrogen Corporation) using the BamHI
site in the MCS. EBNA 6 cDNA was subcloned from a
previously described vector (Young et al., 1997) using the
HindIII site and cloned directly into HindIII-restricted
pBlueBacHis. Protein expression was performed accord-
ing to the manufacturer’s recommendations. EBNAs 3
and 6 recombinant proteins were purified from baculo-
virus cells using the Xpress System (InVitrogen).
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